S. Korean pharma giants drive surge in derma cosmetics sales -

086450 Stock  KRW 15,540  10.00  0.06%   
About 61% of DongKook Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in DongKook Pharmaceutical Co suggests that many traders are alarmed regarding DongKook Pharmaceutical's prospects. The current market sentiment, together with DongKook Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use DongKook Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
  
S. Korean pharma giants drive surge in derma cosmetics sales

Read at news.google.com
Google News at Macroaxis
  

DongKook Pharmaceutical Fundamental Analysis

We analyze DongKook Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

DongKook Pharmaceutical is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

DongKook Pharmaceutical Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with DongKook Pharmaceutical stock to make a market-neutral strategy. Peer analysis of DongKook Pharmaceutical could also be used in its relative valuation, which is a method of valuing DongKook Pharmaceutical by comparing valuation metrics with similar companies.

Complementary Tools for DongKook Stock analysis

When running DongKook Pharmaceutical's price analysis, check to measure DongKook Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DongKook Pharmaceutical is operating at the current time. Most of DongKook Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of DongKook Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DongKook Pharmaceutical's price. Additionally, you may evaluate how the addition of DongKook Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years